MedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)
EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)
424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
S-1 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
S-1/A - TriSalus Life Sciences, Inc. (0001826667) (Filer)
Fastest customizable press release news feed in the world
Advances TriSalus' Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma Provides Cash Runway through Mid-2024 to Fund Key Milestones TriSalus' Common Stock Expected to Begin Trading on the Nasdaq under Symbol "TLSI" on August 11, 2023 TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tu
MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or the "Company") today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting is being held to vote on certain proposals related to the proposed business combination (the "Business Combination") with TriSalus Life Sciences ("TriSalus"). The Special Meeting has been adjourned until 11:00 a.m. Eastern Time on August 8, 2023. The Special Meeting will still be held virtually via webcast, and stockholders may attend and participate online by visiting https://www.cstproxy.com/medtechacquisition/sm2023. Participants will be able to li
New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company in the process of going public through a business combination transaction (the Business Combination) with MedTech Acquisition Corporation (NASDAQ:MTAC) (MedTech or MTAC), today announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023. TriSalus' ongoing Phase 1 Pressure-Enabled Regional Immuno-Oncology (PERIO-01) (NCT04935229) cl
TriSalus Life Sciences® Inc., ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced new Phase 1 clinical data presented at the American Association for Cancer Research ("AACR") 2023 Annual Meeting taking place in Orlando, Florida, from April 14-19, 2023. The clinical data presented at the AACR 2023 Annual Meeting relates to the Company's ongoing Pressure-Enabled Regional Immuno-Oncology ("PERIO-01") clinical study for uveal melanoma with liver metastases ("UMLM"). The PERIO-01 trial is studying an inve
TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced that James "Jim" Alecxih has joined the Company in the newly created role of President, Device Technology Business. Mr. Alecxih brings to TriSalus more than 30 years of experience in product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus' TriNav® Infusion System ("TriNav®"), including device engineering, device quality, sales, marketing, a
Data Further Supports the Potential of the Company's Therapeutic Platform to Improve Immunotherapy Outcomes for Patients with Liver and Pancreatic Tumors TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today posted an updated investor presentation with new data regarding its ongoing Pressure-Enabled Regional Immuno-Oncology™ ("PERIO™-01" and "PERIO™-02") clinical studies for primary and metastatic liver tumors. The presentation is available on the investor relations section of the Co
TriSalus Life Sciences®, Inc. ("TriSalus" or the "company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced that it has expanded the reach of its ongoing Pressure-Enabled Regional Immuno-Oncology™ ("PERIO™-01" and "PERIO™-02") clinical program. In recent months TriSalus has opened five new PERIO™-01 (NCT04935229) clinical trial sites, at Stanford University Hospitals, University of California Los Angeles, University of Colorado's Anschutz Medical Campus, University of Washington Medical Center and University of Miami's Sylvest
The Company recommends all of its stockholders to vote FOR the Extension Amendment at the upcoming Special Meeting. New York, NY, Dec. 07, 2022 (GLOBE NEWSWIRE) -- MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or the "Company") today announced that on December 7, 2022, it convened and then adjourned, without conducting other business, its special meeting of stockholders (the "Special Meeting") in lieu of its 2022 Annual Meeting of Stockholders from December 7, 2022 to 11:00 a.m. Eastern Time on December 12, 2022. The Special Meeting is being adjourned in order to solicit more votes toward the approval to amend the Company's amended and restated certificate of incorporation
TriSalus Life Sciences®, Inc. ("TriSalus") (the "Company"), an oncology therapeutics company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today filed a presentation for investors with additional information regarding its ongoing Pressure-Enabled Regional Immuno-Oncology™ ("PERIO™ 01") and ("PERIO™ 02") clinical studies for primary and metastatic liver tumors. "We are commercializing our TriNav® Infusion System (TriNav®) and developing SD-101 to potentially enable more patients with liver and pancreatic tumors to benefit from immunotherapeutics and the current
TEL AVIV, Israel and FORT LAUDERDALE, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech"), a publicly traded special purpose acquisition company (SPAC) focused on medical technology, and Memic Innovative Surgery Ltd. ("Memic"), a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that both companies have mutually agreed to terminate, effective immediately, their previously announced business combination agreement dated August 12, 2021 due to market conditions and associated volatility as a result of recent world events. "While we are disappointed that our proposed busines
Live Leadership Updates
TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced that James "Jim" Alecxih has joined the Company in the newly created role of President, Device Technology Business. Mr. Alecxih brings to TriSalus more than 30 years of experience in product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus' TriNav® Infusion System ("TriNav®"), including device engineering, device quality, sales, marketing, a
This live feed shows all institutional transactions in real time.
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13D - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13D - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13D - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13D/A - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13D/A - MedTech Acquisition Corp (0001826667) (Subject)